Northern Trust Corp Harpoon Therapeutics, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.55 - $0.82 $8,406 - $12,532	-15,284 Reduced 28.87%	37,663 $26,000
Q1 2023 May 15, 2023	SELL	$0.65 - $1.37 $29 - $61	-45 Reduced 0.08%	52,947 $39,000
Q2 2022 Aug 12, 2022	SELL	$1.78 - $5.02 $233,838 - $659,477	-131,370 Reduced 71.26%	52,992 $101,000
Q1 2022 May 13, 2022	SELL	$3.54 - $8.08 $24,387 - $55,663	-6,889 Reduced 3.6%	184,362 $916,000
Q4 2021 Feb 08, 2022	SELL	$5.69 - $7.83 $38,737 - $53,306	-6,808 Reduced 3.44%	191,251 $1.44 Million
Q3 2021 Nov 15, 2021	SELL	$7.88 - $14.0 $89,122 - $158,340	-11,310 Reduced 5.4%	198,059 $1.57 Million
Q2 2021 Aug 13, 2021	BUY	$13.81 - $23.25 $423,373 - $712,775	30,657 Added 17.15%	209,369 $2.9 Million
Q1 2021 May 12, 2021	BUY	$17.65 - $24.16 $373,050 - $510,645	21,136 Added 13.41%	178,712 $3.74 Million
Q4 2020 Feb 11, 2021	SELL	$12.83 - $17.84 $75,312 - $104,720	-5,870 Reduced 3.59%	157,576 $2.62 Million
Q3 2020 Nov 16, 2020	BUY	$11.01 - $18.52 $125,414 - $210,961	11,391 Added 7.49%	163,446 $2.78 Million
Q2 2020 Aug 14, 2020	BUY	$11.11 - $24.72 $686,342 - $1.53 Million	61,777 Added 68.43%	152,055 $2.53 Million
Q1 2020 May 14, 2020	BUY	$10.74 - $16.32 $104,027 - $158,075	9,686 Added 12.02%	90,278 $1.04 Million
Q4 2019 Feb 14, 2020	SELL	$12.94 - $20.58 $67,896 - $107,983	-5,247 Reduced 6.11%	80,592 $1.19 Million
Q3 2019 Nov 13, 2019	BUY	$10.93 - $17.47 $547,527 - $875,142	50,094 Added 140.14%	85,839 $1.17 Million
Q2 2019 Aug 13, 2019	BUY	$10.0 - $13.03 $30,720 - $40,028	3,072 Added 9.4%	35,745 $465,000
Q1 2019 May 13, 2019	BUY	$9.47 - $17.01 $309,413 - $555,767	32,673 New	32,673 $309,000

Others Institutions Holding HARP

# of Institutions

Shares Held

353K

Call Options Held

Put Options Held

View Full List

About Harpoon Therapeutics, Inc.

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

More about HARP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account